Legacy Pharmaceutical Packaging is recalling 40 repackaged lots of Losartan tablets, a prescription medication used to treat high blood pressure and congestive heart failure.
The product contains trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA), a potential human carcinogen.
Legacy has not received any reports of adverse events to date.
The following product, packaged in 30-count bottles, is being recalled:
| LEGACY NDC# | Name and Strength | Count | Legacy Lot # | Expiry |
|---|---|---|---|---|
| 68645-577-54 | Losartan Potassium Tablets USP 25 mg | 30 | 180952 | 10/2019 |
| 68645-577-54 | Losartan Potassium Tablets USP 25 mg | 30 | 180953 | 12/2019 |
| 68645-577-54 | Losartan Potassium Tablets USP 25 mg | 30 | 181086 | 09/2019 |
| 68645-577-54 | Losartan Potassium Tablets USP 25 mg | 30 | 181572 | 01/2020 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 180921 | 09/2019 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 180922 | 10/2019 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 180923 | 11/2019 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 180924 | 11/2019 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 181118 | 11/2019 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 181119 | 10/2019 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 181407 | 11/2019 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 181408 | 12/2019 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 181573 | 02/2020 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 181725 | 02/2020 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 181726 | 02/2020 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 181948 | 03/2020 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 181960 | 02/2020 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 182385 | 03/2020 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 182386 | 03/2020 |
| 68645-578-54 | Losartan Potassium Tablets USP 50 mg | 30 | 182387 | 03/2020 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 180886 | 11/2019 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 180887 | 12/2019 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 180888 | 12/2019 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 180905 | 12/2019 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181123 | 09/2019 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181124 | 10/2019 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181125 | 08/2019 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181351 | 11/2019 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181352 | 12/2019 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181551 | 11/2019 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181628 | 06/2020 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181629 | 06/2020 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181727 | 06/2020 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181728 | 06/2020 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181890 | 03/2020 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181891 | 06/2020 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 181897 | 06/2020 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 182114 | 03/2020 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 182119 | 06/2020 |
| 68645-579-54 | Losartan Potassium Tablets USP 100 mg | 30 | 182120 | 06/2020 |
The recalled product, which can be identified by checking the product name and repackaged lot number on the bottle, was distributed by pharmacies nationwide.
What to do
Patients who have the recalled product should return it to the dispensing pharmacy.
Consumers with questions regarding this recall should contact their dispensing pharmacy during normal business hours or their physician or healthcare provider if they have had any problems related to taking or using the product.
Keep an eye on your inbox, the lastest consumer news is on it's way!
Share your Comments